Quick Answer
Fulcrum Therapeutics, Inc. reported Total Assets of $366.28 million for fiscal year 2025.
Fulcrum Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $366.28M | +40.5% |
| 2024 | $260.72M | +1.2% |
| 2023 | $257.69M | +13.7% |
| 2022 | $226.69M | -3.5% |
| 2021 | $235.00M | +81.4% |
| 2020 | $129.58M | +17.3% |
| 2019 | $110.44M | +28.8% |
| 2018 | $85.77M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $214.86M | -23.0% | -6.1% |
| June 30, 2025 | $228.84M | -22.2% | -5.7% |
| March 31, 2025 | $242.65M | +4.3% | -6.9% |
| December 31, 2024 | $260.72M | +1.2% | -6.6% |
| September 30, 2024 | $279.01M | +0.0% | -5.2% |
| June 30, 2024 | $294.26M | -2.0% | +26.5% |
| March 31, 2024 | $232.59M | -27.6% | -9.7% |
| December 31, 2023 | $257.69M | +13.7% | -7.6% |
- Fulcrum Therapeutics, Inc. showed an increase of +40.5% in Total Assets compared to the prior fiscal year.
- Over the 2018–2025 period, Fulcrum Therapeutics, Inc.’s total assets has grown by 327.0% (from $85.77 million to $366.28 million).
- The most recent figure is from Fulcrum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: